Astria Therapeutics Files Q1 2025 10-Q
| Field | Detail |
|---|---|
| Company | Astria Therapeutics, Inc. |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, financing
TL;DR
Astria Therapeutics Q1 10-Q filed. Financials look stable, past offerings noted.
AI Summary
Astria Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position, including changes in Additional Paid-In Capital and Retained Earnings. The filing also references past financing activities such as an Underwriting Public Offering in February 2024 and an At-Market Offering.
Why It Matters
This filing provides insight into Astria Therapeutics' financial health and capital structure as of Q1 2025, which is crucial for investors assessing the company's operational capacity and future funding.
Risk Assessment
Risk Level: medium — Biotech companies like Astria Therapeutics often carry inherent risks due to the nature of drug development and regulatory approvals, which can significantly impact financial performance.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
- 20250513 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Astria Therapeutics, Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of reporting period
- February 2024 (date) — Date of Underwriting Public Offering
- 22 BOSTON WHARF ROAD (address) — Company business and mailing address
- BOSTON (location) — Company city
- 02210 (zip_code) — Company zip code
FAQ
What were the significant changes in Astria Therapeutics' Additional Paid-In Capital during the reported period?
The filing indicates changes in us-gaap:AdditionalPaidInCapitalMember for the periods ending March 31, 2025, December 31, 2024, and March 31, 2024, suggesting capital raising or stock-related transactions.
What specific financing activities are referenced in the filing for 2024?
The filing references 'UnderwritingPublicOfferingFebruary2024FinancingMember' and 'AtMarketOfferingMember' for the period of January 1, 2024, to March 31, 2024.
What is Astria Therapeutics' primary business sector?
Astria Therapeutics, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]' according to its Standard Industrial Classification.
What was the previous name of Astria Therapeutics, Inc.?
The former company name was CATABASIS PHARMACEUTICALS INC, with a date of name change on January 27, 2009.
Where is Astria Therapeutics, Inc. located?
The company's business and mailing address is 22 BOSTON WHARF ROAD, 10TH FLOOR, BOSTON, MA 02210.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Astria Therapeutics, Inc..